Explo-Lab near Etobicoke ON (1485 Result(s))

Krins lifesciences office is based in Canada, serving across North America. Krins lifesciences is not only selling Laboratory Equipment but also execute on client site IQ,OQ, PQ, Calibration and Validation for Equipment as per GMP and USP guidelines. Krins lifesciences distribute and sells ASTM Standard Laboratory Glassware, Quality Laboratory flasks, Specimen bags, Laboratory Specimen container, ACS and AR grade Chemicals, Microbiology Media and Consumables, Membrane Filters and many more laboratory consumables with Industrial and all kind of relevant products. Feel Free to visit our website and contact this company for any of your need if looking for products and services for pharmaceutical, cosmetic, nutraceuticals, hospitals, pharmacy, Biotechnology companies.

At Core Diagnostic Imaging - Cardiology Clinic in Mississauga, our team of experienced and attentive technicians perform full cardiac services, including: consultations, ambulatory blood pressure solutions, Holter monitor examinations, echocardiograms and ECGs. For complete cardiac care, give our clinic a call!

Dixie X-ray Associates Ltd. ('Dixie') is comprised of a group of 13 radiologists providing imaging services to Mississauga and North York since 1975 and Vaughan area since 2005. Dixie radiologists provide imaging services to Humber River Regional Hospital as well as operating 6 Independent Health Facilities (IHFs). At these IHFs, Dixie has a referral base of more than 350 physicians evaluating roughly 600 patients per day.

Often, pharmaceutical companies avoid new laboratory testing methodologies preferring to stick to established procedures for drug development so as to avoid any potential regulatory ambiguity. This tendency to avoid new methodologies and regulatory scrutiny sometimes leads to slower progress, higher costs and lower probability of new product approvals. Furthermore, some pharmaceutical firms severely restrict academic research-based modifications to established laboratory testing procedures in drug development because of their concern over triggering costly adjustments to the established regulatory framework.